antiarrhythmic agents have received much attention recently. Such drugs are generally designated as class III antiarrhythmics, because they prolong action potential duration (APD) and/or QT interval in the absence of significant effects on conduction velocity.' However, until recently, all the available K' channel blockers have been relatively nonselective, blocking more than one K' channel, other channels, and receptors as well. Recently, new agents have been developed that not only affect APD selectively but affect particular cardiac repolarizing K' currents selectively. These include tedisamil, which blocks the transient outward current (Io2); glibenclamide, which blocks the ATP-dependent K' channel [IK(ATP)] and prolongs APD selectively during ischemia3; UK66,914, which blocks the delayed rectifying K' current (IK)4,5; and RP58866, an inwardly rectifying K' current (IK1) blocker.6-8 These agents make it possible to examine the value of selective blockade of an individual K' current as a mechanism for suppression of arrhythmias.
Until recently, the majority of work on class III agents has focused on IK blockers. Hitherto, it has proven difficult to unequivocally link blockade of a particular channel to arrhythmia suppression, since one cannot measure channel block and arrhythmia suppression contiguously. We have shown that UK66,914, a new and highly selective IK blocker, widens QT interval and reduces the incidence of reperfusion-induced arrhythmias by more than 50% in rabbit, a species possessing functional cardiac IK,9 whereas in rat, a species deficient in IK,'0 the drug is devoid of activity." This shows that IK block is a specific mechanism for suppression of ventricular fibrillation (VF) during reperfusion. There is currently much interest in blockade of IK(ATP) and its effectiveness as an antiarrhythmic mechanism, but results are in conflict with some studies that show IK(ATP) blockers to be beneficial3"12 and others that find them ineffective.'3"4 Block of I, has been examined by Tsuchihashi and Curtis using tedisamil. '5 Although tedisamil had no effect on the incidence of ischemia-or reperfusion-induced VF in rat in vitro, it decreased the duration of VF once it had started. In rat in vivo, tedisamil reduces ischemia-induced VF incidence,'6 although this occurs only at high doses beyond the range over which the drug is selective for IJ,.2
Until recently, there has been very little information on the utility of IK1 blockade as an antiarrhythmic mechanism. This is primarily a consequence of the lack of selective agents available to probe this channel. In the present study, our aim was to investigate the effect Of IK1 blockade on arrhythmias and QT interval using the novel IK1 blocker RP58866 (Figure 1 ). This agent has been characterized pharmacologically. At concentrations up to 30 ,tmol/L, RP58866 is a highly selective blocker of IK1 and has no effect on inward currents (INa and Ica) or other potassium currents [IK and IK(ATP)I; it prolongs APD, QT interval, and atrial, nodal, and ventricular refractory periods with no effects on conduction velocity or excitability, and it has no effect on resting membrane potential.6-8"17 Thus, at concentrations up to 30 umol/L, RP58866 is a highly selective tool for probing the utility of lK, blockade as an antiarrhythmic mechanism.
We investigated the effects of RP58866 in three species: rat, rabbit, and marmoset. Rat was used as a first-line bioassay. Since rat ventricle possesses no functional IK'0 18 and since neither lK blockers'9 nor selective Ito blockers'520 possess antifibrillatory activity in the perfused rat heart, the preparation is particularly suited to detecting potentially antiarrhythmic effects repolarization, was evaluated as described previously.27 A traction-type coronary occluder consisting of a silk suture (Mersilk, 4-0) threaded through a polyethylene guide was used for coronary occlusion. The suture was positioned loosely around the left main coronary artery beneath the left atrial appendage. Regional ischemia was induced by tightening the occluder and reperfusion by releasing it.
To exclude the possibility that any beneficial effects seen in rat studies are the result of the unusual cardiac electrophysiology of the rat,1529 we repeated essential parts of the studies in rabbit, which has markedly different cardiac action potential morphology, heart rate, and intracellular cation content. To examine the actions of RP58866 in an animal species presumed to be more closely allied to human, studies were performed in primate. Marmosets (male Callithrix jaccus; 300-350 g; n=9-12 per group) were anesthetized with Saffan (a mix of 0.9% a-vaxilone plus 0.3% a-dolone, of which we gave 2 mL/kg i.m.). The heart was arrested and exsanguinated in vivo by insertion of a 23-gauge needle into the left ventricle for infusion of ice-cold Krebs' solution (constituents as described above for rat studies). This was done primarily because the animals were used jointly in separate studies requiring in vivo exsanguination of other organs (e.g., brain). Cardiac excision and LangendorfF perfusion were performed as described above for rat and rabbit.
Experimental Protocols
Ischemia-induced arrhythmias in unpaced rat hearts. The first protocol was designed to allow identification of antiarrhythmic activity of RP58866 and used the isolated rat heart model. Hearts (n =12 per group) were perfused for an initial 5 minutes with salt solution (constituents described above), then solution was switched in a randomized, blinded fashion to one of four solutions modified by addition of stock solutions to contain 0-, 1-, 3-, or 10-,mol/L RP58866. The 0-,mol/L stock solution was vehicle (deionized water). After a further 5 minutes of perfusion, the left coronary artery was occluded. After 30 minutes of ischemia, the occluder was released to achieve reperfusion.
Reperfusion-induced arrhythmias in unpaced rat hearts. Owing to the expected high incidence of sustained VF in the control group during 30 minutes of ischemia,19,20 a separate study was performed to investigate the effect of the drug on reperfusion-induced arrhythmias. Hearts (n= 10 per group) were perfused, randomized to one of four solutions (0-, 1-, 3-, or 10-,umol/L RP58866), and subjected to regional ischemia as above. In these hearts however, the occluder was released to achieve reperfusion after a shorter duration of ischemia (10 minutes). This duration of ischemia was used because, although it is associated with a high susceptibility to reperfusioninduced VF, it is sufficiently brief to preclude a high incidence of sustained ischemia-induced VF,25 which would otherwise interfere with assessment of reperfusion-induced arrhythmias in this model.
Arrhythmias in paced rat hearts. In previous studies we found that (8- (PRc) because (unlike QT) it is rate-dependent in rat. 38 Ischemia-and reperfusion-induced arrhythmias in rabbit hearts. Hearts (n = 12 per group) were subjected to 30 minutes of ischemia as for rat studies. We were able to use the same rabbits for study of ischemia-and reperfusion-induced arrhythmias, because isolated hearts from this species have a much lower susceptibility to ischemia-induced sustained VF than rat. 39 To limit animal use, we examined only two groups, control hearts and 3-,umol/L RP58866.
Ischemia-and reperfusion-induced arrhythmias in marmoset hearts. There are no published data on ischemia or reperfusion arrhythmias in marmoset. In the marmoset studies, we followed a protocol similar to that for rat and used similar perfusion solution. Hearts were subjected to 30 minutes of ischemia by ligation of the left anterior descending coronary artery close to its origin at a position approximately equivalent to that for rat and rabbit studies. Two groups were studied, control hearts (n=12) and 3-,umol/L RP58866 (n=9).
Measurement of Occluded-Zone Size
Two independent methods were used to verify occlusion and to delineate the occluded zone from uninvolved tissue. First, coronary flow was measured by timed collection of coronary effluent in a graduated cylinder; occlusion was verified by comparing flow at 1 minute before occlusion with flow at 1 minute after occlusion and was quantified in terms of the percentage reduction in flow. Second, at the end of 5 minutes of reperfusion, readmission of flow was verified and the size of the formerly occluded zone was quantified by the disulfine blue dye exclusion method.25 Occluded-zone size was quantified as a percentage of total ventricular weight. Values of coronary flow in the uninvolved tissue and the reperfused zone were calculated from the total coronary flow and the weights of the occluded zone and the uninvolved zone, as described previously. 26 We expected occluded-zone sizes of approximately 40% total ventricular weight in rat and rabbit." The deficiency of coronary collaterals in rat and rabbit40 means that occluded zone determined by dye is equivalent to zone by flow reduction.26 In marmoset (for which no data exist), we aimed for an occluded-zone size equivalent to that in the other species by placing the coronary occluder in an equivalent location. Collateral flow in marmoset was determined by comparing estimates of occluded-zone size measured by flow reduction and dye methods, since dye exclusion delineates the zone of underperfusion, whereas flow reduction defines the extent of global reduction. Collateral flow was calculated as milliliters per minute per gram of underperfused myocardium and was expressed as percent of flow in the uninvolved zone (delineated by dye).
Exclusion Criteria
Any rat heart with a sinus rate of <250 beats per minute or a coronary flow of > 18 mL/min or <8 mL/min at 5 minutes before the onset of ischemia (and before randomization) was excluded. Likewise, any rabbit with a sinus rate of <200 beats per minute or a coronary flow of >80 mL/min or <35 mL/min was excluded.3' Exclusion criteria for marmoset could not be defined before the study because no data base exists. Therefore, we applied le Chatlier's principle and excluded any heart for which heart rate or coronary flow values lay more than 2 SD from the group mean. For all three species, any heart not in sinus rhythm during the 2 seconds before reperfusion was excluded from the reperfusion sample.
Arrhythmia Diagnosis and ECG Analysis
A digital storage-type oscilloscope (model DS0400, Gould) and a Gould chart recorder (model RS3200) were used in the identification and analysis of waveforms and diagnosis of arrhythmias. Arrhythmias were defined according to the Lambeth Conventions4' with slight modification. ' From the ECG, the incidence and the time to onset of arrhythmias, the RR interval, and the QT interval measured at the point of 100% repolarization (or at 90% repolarization in paced heart studies) with on-screen cursors were obtained (see Figure 2) . In isolated rat heart, QT is rate independent, but in rabbit, QT appears to vary with heart rate. For this reason, we have presented rat QT data uncorrected (QT), but have corrected rabbit data using Zbinden et al's42 formula (QTz=QT/RR). Appro incidence was significantly reduced (Figure 3 ). higher concentrations of drug developed VF, so onset times could not be assessed in these groups). When ischemia-induced arrhythmias were analyzed in relation to their time course of occurrence, it was found that RP58866 reduced the occurrence of VPB, VT, and VF to a similar degree in each successive 5-minute interval, although the effects were statistically significant only when control incidences were sufficiently high to permit "detection" of the effects (Figure 4) .
RP58866 was also concentration-dependently effective against reperfusion-induced arrhythmias in rat (Figure 5) . The 3-,umol/L concentration abolished VF, and the 10-,umol/L concentration abolished VF and VT and reduced VPB incidence (p<0.05). RP58866 significantly widened QT and RR intervals (Table 1) before and during ischemia.
RP58866 (examined at the highest concentration only) retained its antiarrhythmic actions on ischemiaand reperfusion-induced arrhythmias when hearts were paced at a frequency of 5 Hz (Figure 6 ). In paced hearts, the onset of the first ischemia-induced arrhythmia was significantly delayed by the drug from 2.70±0.02 to 3.0+0.04 logl0 seconds. The drug also retained its ability to widen QT interval when hearts were paced (Table 2) . RP58866 had no effect on coronary flow or occludedzone size. Coronary flow 1 minute before the onset of ischemia was 12±0.7, 10±0.8, 12±0.6, and 12± 1.1 mL-min-l g-1 in control, 1-,mol/L, 3-,umol/L, and 10-,umol/L groups, respectively (p=NS), and recovery of coronary flow on reperfusion was 9+1.5, 12+2.0, 11±1.1, and 9+1.2 mL min-l g-1 of reperfused tissue, respectively (p=NS). Occluded-zone sizes were similar in each group, values being 41±3%, 40±3%, 40±2%, and 42±2% of total ventricular weight with increasing concentrations of drug (p=NS). Thus, antiarrhythmic effects were not secondary to changes in flow or changes in occluded-zone size.
Potassium Dependence of RP58866's Effects on QT, RR, and PR Intervals in Rat
The effects of elevation of extracellular K' on the ability of RP58866 to widen QT interval were examined in the absence of ischemia in separate groups of rat hearts ( Figure 7 ). Switching from 8-mmol/L K' to 3-mmol/L K' perfusion solution had no significant effect on QT (93 ±5 versus 99±8 msec). In 3-mmol/L K' solution, 3-ttmol/L RP58866 widened QT within 1 minute to 131±12 msec (p<0.05) and continued to widen it to 156±11 msec (p<0.05) after 9 minutes. When K' was increased to 8 mmol/L in the presence of drug, there was a significant QT shortening (p<0.05) to 133-12 msec, although by 9 minutes after the change, QT had lengthened to 141 ± 10 msec.
Switching from high to low K' in the absence of drug widened RR from 206±9 to 221±7 msec (p<0.05). On introduction of RP58866, RR was further widened to 264±11 msec (p<0.05). When K' was increased to 8 mmol/L in the presence of drug, no additional bradycardia was seen.
RP58866 had no effect on PR interval corrected for heart rate (PRJ). PR, was significantly shortened, from 47±1 to 40±2 msec, after switching from 8 mmol/L to 3 Figure 6B shows that RP58866 had no proarrhythmic activity. Reperfusion-induced VF occurred with a high incidence (eight of 12) in control rabbit hearts (as expected39), permitting analysis of the antiarrhythmic effects of RP58866. RP58866 significantly reduced the incidence of the most severe reperfusion-induced arrhythmias (VF and VT) but had no effect on VPB incidence ( Figure 8B) .
As in rat, RP58866 elicited significant bradycardia and caused significant widening of QT interval (corrected for alterations in rate; were significantly reduced by drug (from 36% to 0% and from 91% to 33%, respectively; p<0.05). VF incidence was very low in marmoset during ischemia, but there was no proarrhythmia ( Figure 7A ). During reperfusion, RP58866 significantly reduced VF incidence, from 64% to 11%, but had no significant effects on either VT or VPB incidence ( Figure 9B ). RP58866 elicited bradycardia and QT widening in marmoset (Tables 4 and 5 ). Changes were similar to those seen in rat and rabbit. QT was expressed in three different ways, since appropriate heart rate correction is not known for marmoset. QT uncorrected for heart rate was widened in marmoset to an extent similar to that in rat. For example, values 10 minutes after the onset of ischemia were increased by 70% in marmoset and 82% in rat by 3 umol/L of drug (compared with timematched control values). Likewise, QTz was widened to a similar extent in marmoset and rabbit 10 minutes after ischemia onset (by 18% and 16%, respectively). This indicates that when appropriate (species-dependent) correction for heart rate is applied, RP58866 affects QT similarly in different species. RP58866 had no effect on flow before or during ischemia (Table 5) or on recovery of flow on reperfusion (13+ 1 mL -mind g`1 of reperfused tissue versus 15+1 mL* min 1. g`in control and drug-treated hearts, respectively; p=NS). Occluded-zone sizes were similar in control and drug groups whether measured by flowreduction or dye-exclusion methods (in control group, 45±1% by dye method and 45±3% by flow reduction versus in drug-treated hearts, 47±3% by dye method control hearts (0 gmol/L). The drug significantly reduced the incidence of reperfusion-induced VF, but had no significant effect on VT or VPB. and 46±3% by flow-reduction measurements; p=NS). The consistency between flow and dye measures of occluded-zone size, reminiscent of equivalent data for rat,26 indicates an absence of functional coronary collateral vessels in this species, as is the case for rat and rabbit.40 The similarity between control and drug groups for each of these estimates indicates an inability of RP58866 to increase collateral flow in this species. Findings were similar for rat and rabbit.
Discussion
Class III antiarrhythmic drugs represent a potential alternative to class I drugs in ischemic heart disease, given the problems associated with the latter45 and in view of the antiarrhythmic efficacy of agents such as D-sotalol. 46 The present study is the first to examine the potential of a new and highly selective lKi blocker in prophylaxis of ischemia-and reperfusion-induced arrhythmias. We observed consistent antiarrhythmic effects in all three species studied (rat, rabbit, and marmoset), with effects being concentration-dependent where studied (in rat). Effects were accompanied by equivalent QT widening and bradycardia in each species.
The first question to consider is whether these effects were direct or secondary to "anti-ischemic" actions. An indirect antiarrhythmogenic action (e.g., via some antiischemic property) can be ruled out. The reasons for this are as follows. First, anti-ischemic interventions delay the onset of ischemia-induced and reperfusion-induced VF susceptibility (shown explicitly in the rat model57); they do not suppress arrhythmias throughout the time course of ischemia, in contrast to the findings with RP58866 in the rat (Figure 4) . Second, pacing rat hearts failed to reverse the protective effects of the drug, as would be expected if anti-ischemic actions contributed to the antiarrhythmic effects. Therefore, the drug can be presumed to have affected arrhythmias as a consequence of a direct effect on cardiac electrophysiology. We used the rat to examine the role of ventricular IKI block versus other cellular mechanisms in mediating the antiarrhythmic effects. Since previous work has shown that UK66,914, a selective 1K blocker,5 has no effect on heart rate, QT interval, or arrhythmias in rat'9; since adult rat ventricle is deficient in functional IK10'18; and since RP58866 does not block 'K over the concentration range used in the present study,6-8 then 'K block can be excluded as a mechanism contributing to the drug's antiarrhythmic effects. Also, since previous work has shown that I,. block with tedisamil is ineffective in preventing VF in the isolated rat heart model'5 and since RP58866 does not alter the action potential shape in the "notch" region where I, is active,7,8 then I,. block would not appear to be sufficient to explain any antiarrhythmic effect of the drug in rat. In addition, RP58866 has no effect on INa, IK(ATP), or T or L calcium currents,67 so block of these currents can be excluded as mechanisms contributing to the drug's effects on arrhythmias. However, RP58866 does have established effects on IK1. These effects lead to APD widening at voltages negative to 1 mV.8 Furthermore, in contrast to UK66,914,19 RP58866 widens QT and prevents VF in rabbit and in rat (UK66,914 is effective in rabbit but has no pharmacological activity in rat). On the basis of these data, 1K1
blockade appears to be a mechanism sufficient to account for the antiarrhythmic effects observed in rat in the present study.
An indication that the drug may be a specific IKI blocker but not necessarily a completely selective blocker is that it caused pronounced bradycardia in all three species tested. This is puzzling, because although the periphery of the sinoatrial node has been shown to possess 1K1 ,58 the center of the node, which is responsi- The present study demonstrated, for the first time, pharmacological prevention of both ischemia-and reperfusion-induced arrhythmias in isolated perfused marmoset hearts. This model has not previously been used for such studies because of high costs. We were able to perform the present studies because a limited number of hearts were made available to us by colleagues in our department. The lack of data base with this model is a disadvantage. However, the model was used under the assumption that because it is primate, it is likely to be more "relevant" to humans. The lack of data base, however, does mean that we cannot say whether RP58866 is more or less effective than other drugs in the model. The important point from the primate studies is that the drug was effective in the model, reducing arrhythmias and widening QT interval in a manner equivalent to that seen in rat and rabbit.
The model itself appears to be more similar to the rabbit than the rat model in terms of heart rate, QT interval, heart size, and susceptibility to ischemia-and reperfusion-induced arrhythmias. Occluded-zone sizes were similar in control and drug groups, whether measured by dye or flow reduction (as was the case for the other two species used). The latter indicates that the marmoset heart, like that of the rat and rabbit, is deficient in functional coronary collaterals.
Finally, although we have established that IK, blockade is a mechanism sufficient to account for the effects of RP58866 on VF during ischemia and reperfusion by lKi blockade, we have not addressed the mechanism by which lK, blockade leads to VF suppression at the syncytial level (e.g., reentry, abnormal automaticity, flow of injury current). This is a difficult question to address. During a 30-minute period of ischemia in the isolated rat heart (the model used most intensively in the present studies), initiation of VF appears to occur via flow of injury current between ischemic and nonischemic tissue.62 IKi blockade by RP58866 may be capable of preventing this from occurring either by reducing diastolic injury potential (by causing partial depolarization of nonischemic tissue) or by reducing systolic injury potential (by altering the shape of the terminal phase of the action potential). Ischemia-induced VPB and VT and reperfusion-induced VF appear to be initiated by mechanisms other than injury current flow,62 but as yet there is no proof of which of the possible mechanisms is most important.63 However, ischemia-induced VF may be initiated by a mechanism different from that for VT and VPBs2662; moreover, modulation of VPBs preferentially at later (>20 minutes) versus earlier stages of ischemia may indicate that arrhythmogenic mechanisms may vary during a 30-minute period of ischemia as well as between different arrhythmia subtypes.62 Thus, the present observation that RP58866 appears to suppress ischemia-induced VF, VT, and VPBs and to do so equally well at different stages of a 30-minute period of ischemia indicates that it may be inappropriate to view the drug as having a selective action on any specific arrhythmogenic mechanism (e.g., flow of injury current versus reentry). Instead, the drug, via IK1 blockade, may have a broader spectrum of action on so-called syncytial arrhythmogenic mechanisms.
In conclusion, we have demonstrated the first observation of antiarrhythmic effects of a selective lKi blocking drug in the setting of acute ischemia and reperfusion in three species, including a primate. lK, blockade by RP58866, producing a widening of QT interval (which, unusually for a K' channel blocker, appears to persist with heart rate maintained by pacing and in tissue exposed to elevated K' concentration), may represent a useful new antiarrhythmic mechanism. Other as yet undiscovered pharmacological actions may contribute to the antiarrhythmic effects and the QT widening observed, although their invocation is not necessary.
